Endpoints News
Novo Nordisk's parent company's assets shrink Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T W Thu F
12 March, 2026
95% of AI pilots fail to deliver R&D impact
Is your biologics discovery built to maximize the impact of AI?
sponsored by Cradle
presented by Southern Star Research
South­ern Star Re­search ex­pands Asia foot­print through strate­gic in­vest­ment in Ex­pec­to Health Sci­ence
spotlight
In Focus
After touching the $1T club, Eli Lilly CEO David Ricks is making the moves to stay there
ENDPOINTS NEWS
news
Lilly warns of impurity risk in certain compounded forms of Mounjaro and Zepbound
ENDPOINTS NEWS
 
Watch: Who won the Hims vs. Novo feud?
ENDPOINTS NEWS
Novo Holdings’ assets fell by a third in 2025 as Novo Nordisk’s value sank
ENDPOINTS NEWS
Endpoints webinars
Mar 24
11:30 am ET
From structure to selectivity: Federated AI for collaborative binding affinity prediction
Rhino Federated Computing
US Pharma and Biotech Summit - May 14, 2026
US biopharma still leads the world in high-risk drug development, but the road from innovation to access has never been harder to predict. Hear from top executives and investors on how they’re navigating what’s next. Join us.
in case you missed it
1.
FDA merges adverse event trackers into one database, including vaccine side effects
ENDPOINTS NEWS
2.
Evotec plans up to 800 job cuts, four site closures in next phase of reorganization
ENDPOINTS NEWS
3.
Lilly plots GLP-1 pill production boost in China, $500M pledge to South Korea
ENDPOINTS NEWS
4.
News Briefing
UCB says Bimzelx tops Skyrizi in trial; Xenon, Dianthus set share sales
ENDPOINTS NEWS
5.
RA Capital, Forbion appear to back Harbour's CTLA-4 partner Solstice
ENDPOINTS NEWS
6.
RFK Jr.’s department is revealing its thoughts about women's health
POLITICO
7.
A Third of Americans Have Cut Spending or Borrowed Money for Health Care
THE NEW YORK TIMES
Elizabeth Cairns
.

Compounded forms of weight loss drugs are in the news again this morning, with Lilly alleging that some of them are dangerous. The coverage of this issue by Endpoints' Health Tech team is second to none — stay tuned for further analysis of how this situation is developing.

.
Elizabeth Cairns
Senior Biopharma Journalist, Endpoints News
Endpoints News
2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com
web twitter linkedin